Research programme: heparanase inhibitors - UCB

Drug Profile

Research programme: heparanase inhibitors - UCB

Alternative Names: Heparanase inhibitors research programme - Celltech Group; OGT 2492

Latest Information Update: 13 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Small molecules
  • Mechanism of Action Heparanase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 09 Jan 2009 Wilex acquires preclinical oncology drug programmes from UCB Pharma SA
  • 06 Mar 2006 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
  • 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top